Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079047 | 1.00 | TAAR1 (0.48) | TAAR1LMNAIDO1L3MBTL1ALDH1A1 | |
| SCHEMBL1515819 | 0.83 | ACHE (0.38) | TAAR1LMNAIDO1L3MBTL1ALDH1A1 | |
| SCHEMBL1807270 | 0.82 | CES2 (0.39) | TAAR1LMNAIDO1ALDH1A1HTT | |
| SCHEMBL7461135 | 0.82 | TDP1 (0.38) | LMNAALDH1A1HTTSMN1; SMN2KMT2A | |
| SCHEMBL1980395 | 0.80 | CES2 (0.38) | TAAR1LMNAIDO1MPO | |
| SCHEMBL8585700 | 0.80 | PTPN1 (0.44) | LMNAALDH1A1HTTKMT2A | |
| SCHEMBL1115116 | 0.79 | ERN1 (0.52) | TAAR1ALDH1A1MPO | |
| SCHEMBL15994927 | 0.79 | CYP1A2 (0.38) | TAAR1LMNAIDO1L3MBTL1ALDH1A1 | |
| SCHEMBL6927900 | 0.79 | SMN1; SMN2 (0.39) | TAAR1LMNAL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6462646 | 0.78 | CTSS (0.43) | TAAR1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111808100-A | Indole alkaloid compound and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2020-10-23 | — | — | CN | claimed |
| CN-102311325-A | Method for preparing prasugrel intermediate cyclopropyl-2-fluorine benzyl ketone | SHANDONG XINHUA PHARMACEUTICAL | 2012-01-11 | — | — | CN | claimed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025014719-A2 | TROPANE COMPOUNDS FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-16 | — | — | WO | disclosed |
| EP-4384519-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | Albert-Ludwigs-Universität Freiburg (DE) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| CN-115353539-B | Application of oligonucleotide-tetrahydrothiazole compounds in synthesis of gene coding compound library | 康龙化成(宁波)科技发展有限公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017152-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2023-02-16 | — | — | WO | disclosed |
| EP-0254078-B1 | PYRAN DERIVATIVES | BASF Aktiengesellschaft (DE) | 1991-02-06 | — | — | EP | disclosed |
| EP-0102227-B1 | 2(1H)-PYRIDINONES, USEFUL AS CARDIOTONIC AGENTS, AND THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1989-05-03 | — | — | EP | disclosed |
| EP-0254078-A1 | Pyran derivatives | BASF Aktiengesellschaft (DE) | 1988-01-27 | — | — | EP | disclosed |
| US-4607037-A | Cardiotonic 2(1H)-pyridinones | WARNER-LAMBERT COMPANY (US) | 1986-08-19 | — | — | US | disclosed |
| US-4503061-A | Substituted phenyl-pyridinones as cardiotonic agents | WARNER-LAMBERT COMPANY (US) | 1985-03-05 | — | — | US | disclosed |
| EP-0102227-A2 | 2(1H)-pyridinones, useful as cardiotonic agents, and their production | WARNER-LAMBERT COMPANY (US) | 1984-03-07 | — | — | EP | disclosed |
| US-4267359-A | Novel carboxylic acid esters | ZOECON CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4204071-A | 4-Aryl-3-butenoic acids and lower alkyl esters | ZOECON CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-3984400-A | 11-Desoxy-16-aryl-ω-tetranorprostaglandins | PFIZER INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | TAAR1 3002/4885LMNA 3925/4885IDO1 2116/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | TAAR1 4007/4885LMNA 99/4885IDO1 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.